| Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study AL Sørensen, SU Mikkelsen, TA Knudsen, ME Bjørn, CL Andersen, ... haematologica 105 (9), 2262, 2020 | 110 | 2020 |
| Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis SU Mikkelsen, L Kjær, ME Bjørn, TA Knudsen, AL Sørensen, ... Cancer Medicine 7 (8), 3571-3581, 2018 | 52 | 2018 |
| The role of vitamin C in epigenetic cancer therapy SU Mikkelsen, L Gillberg, J Lykkesfeldt, K Grønbæk Free Radical Biology and Medicine 170, 179-193, 2021 | 35 | 2021 |
| The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention—a pilot study MM Lauridsen, S Mikkelsen, T Svensson, J Holm, C Klüver, J Gram, ... PLoS One 12 (10), e0185412, 2017 | 26 | 2017 |
| Safety and efficacy of combination therapy of interferon-alpha2+ JAK1-2 inhibitor in the Philadelphia-negative chronic myeloproliferative neoplasms. Preliminary results from … SU Mikkelsen, L Kjær, V Skov, ME Bjørn, CL Andersen, OW Bjerrum, ... Blood 126 (23), 824, 2015 | 24 | 2015 |
| B‐cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon‐α2, or combination treatment AL Sørensen, ME Bjørn, CH Riley, M Holmstrøm, MH Andersen, IM Svane, ... European Journal of Haematology 103 (4), 351-361, 2019 | 11 | 2019 |
| Structural aberrations are associated with poor survival in patients with clonal cytopenia of undetermined significance SU Mikkelsen, S Safavi, K Dimopoulos, CJ O’Rourke, MK Andersen, ... haematologica 106 (6), 1762, 2021 | 9 | 2021 |
| B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon-alpha 2, or combination treatment AL Sorensen, ME Bjorn, CH Riley, M Holmstrom, MH Andersen, IM Svane, ... European journal of haematology 103 (4), 351-361, 2019 | 4 | 2019 |
| Portosystemic Hepatic Encephalopathy Scores (PHES) differ between Danish and German healthy populations despite their geographical and cultural similarities MM Lauridsen, LL Grønkjær, JH Atkins, SU Mikkelsen, T Svensson, ... Metabolic Brain Disease 39 (6), 1149-1155, 2024 | 1 | 2024 |
| LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome K Kaastrup, L Gillberg, SU Mikkelsen, AD Ørskov, C Schöllkopf, ... Clinical Epigenetics 15 (1), 91, 2023 | 1 | 2023 |
| 1-49-01 Cerebral function in workers previously exposed to metallic mercury at a chlorine alcali plant K Grunnet, IP Pedersen, J Hansen, S Mikkelsen Journal of the Neurological Sciences, S65, 1997 | 1 | 1997 |
| Oral Vitamin C Supplementation Modulates Inflammatory Cytokines in Clonal Cytopenia of Undetermined Significance and Low-Risk Myeloid Malignancies: Results from EVI-2 Trial A Al-Mousawi, SU Mikkelsen, AB Nielsen, AP Vallentin, AØ Mortensen, ... Blood 144 (Supplement 1), 3201-3201, 2024 | | 2024 |
| Myelodysplastic Neoplasms and the Before and Beyond–Exploring Prognostic Factors and the Therapeutic Role of Vitamin C in Myeloid Malignancies SU Mikkelsen Københavns Universitet, 2023 | | 2023 |
| PF534 COPY NUMBER VARIATIONS AND UNIPARENTAL DISOMY PREDICT POOR SURVIVAL IN PATIENTS WITH IDIOPATHIC CYTOPENIA OF UNDETERMINED SIGNIFICANCE AND ARE ASSOCIATED WITH MACROCYTOSIS SU Mikkelsen, S Safavi, JW Hansen, K Dimopoulos, C O’Rourke, ... HemaSphere 3, 220, 2019 | | 2019 |
| Safety And Efficacy Of Combination Therapy Of Interferon Αlpha-2 And Ruxolitinib In Polycythemia Vera And Low-/Intermediate-1-Risk Myelofibrosis–A One Year Follow-Up Update Of … SU Mikkelsen, L Kjær, ME Bjørn, TA Knudsen, AL Sørensen, V Skov, ... EHA Learning Center 2018, PF620, 2018 | | 2018 |
| Correspondence: KIRSTEN GROENBAEK-kirsten. groenbaek@ regionh. dk SU Mikkelsen, S Safavi, K Dimopoulos, CJ O’Rourke, MK Andersen, ... | | |
